Evidence map›Paper›PMID 40133688›Full record

ReviewFunctional & integrative genomics2025

New approaches of chimeric antigen receptor (CAR)-immune cell-based therapy in gastric cancer; highlight CAR-T and CAR-NK.

Saade Abdalkareem Jasim, Harikumar Pallathadka, G V Sivaprasad, Ashwani Kumar, Yasser Fakri Mustafa, Jaafaru Sani Mohammed, Mamdouh Eldesoqui, Atreyi Pramanik, Rakhimova Khusnidakhon Abdukarimovna, Ahmed Hussein Zwamel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Saade Abdalkareem JasimMedical Laboratory Techniques Department, College of Health and Medical Technology, University of Al-maarif, Anbar, Iraq. saade.a.j@uoa.edu.iq.
Harikumar PallathadkaManipur International University, Imphal, Manipur, India.
G V SivaprasadDepartment of Basic Science & Humanities, Raghu Engineering College, Visakhapatnam, India.
Ashwani KumarDepartment of Life Scienzces, School of Sciences, Jain (Deemed-to-Be) University, Bengaluru, Karnataka, 560069, India.
Yasser Fakri MustafaDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul-41001, Iraq.
Jaafaru Sani MohammedMedical Analysis Department, Tishk International University, Erbil, Iraq.
Mamdouh EldesoquiDepartment of Basic Medical Sciences, College of Medicine, Almaarefa University, 13713, DiriyahRiyadh, Saudi Arabia. mamrah@um.edu.sa.
Atreyi PramanikSchool of Applied and Life Sciences, Divison of Research and Innovation, Uttaranchal University Dehradun, Dehradun, Uttarakhand, India.
Rakhimova Khusnidakhon AbdukarimovnaDepartment of Folk Medicine and Pharmacology, Fergana Public Health Medical Institute, Fergana, Uzbekistan.
Ahmed Hussein ZwamelMedical Laboratory Technique College, The Islamic University, Najaf, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One characteristic that makes gastric cancer (GC) against other cancers is the intricate immune system's reaction, particularly to tenacious inflammation. Consequently, the immunological function is essential to the growth of this malignancy. Tumor immunotherapy has yielded several encouraging outcomes, but despite this, different patients continue to not respond to treatment, and a far larger number become resistant to it. Also, activated CAR-T cells express a majority of immunological checkpoint factors, containing PD1, CTLA4, and LAG3, which counteracts the anti-tumor actions of CAR-T cells. Moreover, cytokine release syndrome is one of the possible adverse responses of CAR-T cell therapy. Therefore, producing universal allogeneic T lymphocytes with potent anti-tumor activity is essential. This study demonstrates current research on this cutting-edge technology, including the composition and mode of action of CAR-NK and CAR-T cells in GC. Also, in this study, we examined recent studies about various specific GC biomarkers that target CAR-T cells and CAR-NK cells.

Indexed as

Immunotherapy, AdoptiveKiller Cells, NaturalReceptors, Chimeric AntigenStomach NeoplasmsHumansT-LymphocytesReceptors, Chimeric AntigenChimeric antigen receptorGastric cancerImmune cellImmunotherapy

Identifiers

PMID40133688

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.